Mitochondrial quality control in the heart: New drug targets for cardiovascular disease

Chang Myung Oh, Dongryeol Ryu, Sungsoo Cho, Yangsoo Jang

Research output: Contribution to journalReview articlepeer-review

13 Citations (Scopus)


Despite considerable efforts to prevent and treat cardiovascular disease (CVD), it has become the leading cause of death worldwide. Cardiac mitochondria are crucial cell organelles responsible for creating energy-rich ATP and mitochondrial dysfunction is the root cause for developing heart failure. Therefore, maintenance of mitochondrial quality control (MQC) is an essential process for cardiovascular homeostasis and cardiac health. In this review, we describe the major mechanisms of MQC system, such as mitochondrial unfolded protein response and mitophagy. Moreover, we describe the results of MQC failure in cardiac mitochondria. Furthermore, we discuss the prospects of 2 drug candidates, urolithin A and spermidine, for restoring mitochondrial homeostasis to treat CVD.

Original languageEnglish
Pages (from-to)395-405
Number of pages11
JournalKorean Circulation Journal
Issue number5
Publication statusPublished - 2020

Bibliographical note

Funding Information:
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), which is funded by the Ministry of Education (2016R1A6A3A04010466 to C.M.O.) and (2017R1D1A1B03032708 to D.R.).

Publisher Copyright:
Copyright © 2020. The Korean Society of Cardiology

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Mitochondrial quality control in the heart: New drug targets for cardiovascular disease'. Together they form a unique fingerprint.

Cite this